Hayashida, Tetsu http://orcid.org/0000-0002-1657-803X
Jinno, Hiromitsu
Mori, Katsuaki
Sato, Hiroki
Matsui, Akira
Sakurai, Takashi
Hattori, Hiroaki
Takayama, Shin
Wada, Masahiro
Takahashi, Maiko
Seki, Hirohito
Seki, Tomoko
Nagayama, Aiko
Matsumoto, Akiko
Kitagawa, Yuko
Article History
Received: 19 August 2017
Accepted: 22 June 2018
First Online: 28 June 2018
Ethics approval and consent to participate
: The study was undertaken in accordance with the Declaration of Helsinki and the study protocol received local approval of the Ethic Committee of Keio University Hospital. Initial approval was obtained on November 27, 2012. Local ethics committees approved the studies in the participating facilities (the Ethic Committee of National Hospital Organization Tokyo Medical Center, the Ethic Committee of Hino Municipal Hospital, the Ethic Committee of Japanese Red Cross Medical Center, the Ethic Committee of Japan Community of Health Care Organization, the Ethic Committee of Federation of National Public Service Personnel Mutual Aid Associations, the Ethic Committee of Tokyo Dental College, the Ethic Committee of Kitasato University School of Medicine, the Ethic Committee of Teikyo University Hospital, the Ethic Committee of Inagi Municipal Hospital). Written informed consent was obtained from all patients prior to screening assessments or enrolment.
: Not applicable.
: T. Hayashida has received grants and/or speaker’s honoraria from Daiichi Sankyo, Eisai, Novartis Pharma, Takeda, AstraZeneca, Chugai within the past three years. Y. Kitagawa has received grants and/or speaker’s honoraria from Daiichi Sankyo, Eisai, Eli Lilly, GlaxoSmithKline, Novartis Pharma, Chugai, Pfizer, Shionogi, Takeda, Otsuka Pharmaceutical within the past three years. Hiromitsu Jinno has received grants and/or speaker’s honoraria from Daiichi Sankyo, Eisai, Novartis Pharma, Chugai, Takeda, Astra Zeneca within the past three years. A. Nagayama owns stock options of Chugai. A. Nagayama’s immediate family member has a leadership position of Chugai and Roche.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.